Literature DB >> 3081065

Prognostically significant classification of immune changes in AIDS with Kaposi's sarcoma.

J Taylor, R Afrasiabi, J L Fahey, E Korns, M Weaver, R Mitsuysau.   

Abstract

Sixteen immunological parameters were assessed quantitatively for their value in providing an immunologically-based and prognostically significant classification of the immune alteration in 97 patients with AIDS and Kaposi's sarcoma (AIDS-KS). The dimensions of reductions in the T4 (T helper-inducer cells) subpopulation of lymphoid cells in the T4-T8 ratio were found to correlate most closely with prognosis. Most other immunological changes did not relate to clinical course. T4 lymphocyte levels greater than 300/microL and a T4-T8 ratio greater than 0.5 indicated a relatively good prognosis, eg, 85% to 95% survival at 12 months. T4 levels less than 100/microL and/or a T4-T8 ratio less than 0.2 had a very poor prognosis, eg, less than 25% survival at 12 months. Intermediate T4 levels and T4-T8 ratios had intermediate prognosis. These immunological findings were found to have independent prognostic value for survival when compared with disease classifications based on tumor stage (I through IV) or on clinical status A (without) or B (with fever, night sweats, or weight loss). Reduced proliferative capacity, increased OKT10 antigen expression, elevated levels of serum IgA, and immune complexes also correlated with prognosis. Elevated levels of serum IgG, cellular HLA-DR expression, and skin test anergy occurred frequently in AIDS-KS but did not have prognostic significance. Variations in level of total lymphocyte, T8 (T suppressor/cytotoxic) cell, gamma FcR receptor-positive cell number, NK activity, or level of serum IgM were less common in AIDS-KS and did not correlate with prognosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081065

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Evaluation of different staging systems for Kaposi's sarcoma in HIV-infected patients.

Authors:  A Antinori; I Izzi; A Ammassari; G Camilli; R Murri; E Tamburrini
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Normal range estimation for repeated immunologic measures.

Authors:  J M Taylor; W G Cumberland; X Meng; J V Giorgi
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

3.  Prognostic factors in acquired immunodeficiency syndrome.

Authors:  J D Wenger; C C Whalen; M M Lederman; T J Spech; J T Carey; J W Tomford; C S Landefeld
Journal:  J Gen Intern Med       Date:  1988 Sep-Oct       Impact factor: 5.128

Review 4.  Immunology of HIV infection and AIDS: memorandum from a WHO/IUIS meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

5.  Subset markers of CD8(+) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection.

Authors:  G Vanham; L Kestens; G Penne; C Goilav; P Gigase; R Colebunders; M Vandenbruaene; J Goeman; G van der Groen; J L Ceuppens
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

6.  Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease.

Authors:  S Zolla-Pazner; D C Des Jarlais; S R Friedman; T J Spira; M Marmor; R Holzman; D Mildvan; S Yancovitz; U Mathur-Wagh; J Garber
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Combination chemotherapy and alpha-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome.

Authors:  F A Shepherd; W K Evans; B Garvey; S E Read; M Klein; M M Fanning; R Coates
Journal:  CMAJ       Date:  1988-10-01       Impact factor: 8.262

8.  A statistical method for assessing change in immunologic parameters in a patient.

Authors:  J M Taylor; S Plaeger-Marshall; J L Fahey
Journal:  J Clin Immunol       Date:  1986-05       Impact factor: 8.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.